Reference 2020-564

REF:       2020-564      

Subject:   Usage of antiretroviral therapies      




I am analysing the usage of antiretroviral therapies. Could you please answer the following four questions?

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:

  • Juluca (rilpivirine/dolutegravir)
  • Dovato (lamivudine/dolutegravir)
  • Triumeq (abacavir/lamivudine/dolutegravir)
  • Tivicay (dolutegravir)
  • Isentress (raltegravir)
  • Biktarvy (TAF/emtricitabine/bictegravir)
  • Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
  • Symtuza (TAF/emtricitabine/darunavir/cobisistat)
  • Odefsey (TAF/emtricitabine/rilpivirine)
  • Descovy (TAF/emtricitabine)
  • Truvada or generic TDF/emtricitabine


Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):

  • for the latest 6-month period
  • for the 6 months from July-December 2019


Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:

  • HIV treatment
  • Pre-exposure prophylaxis (PrEP)


Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:

  • HIV treatment
  • Pre-exposure prophylaxis (PrEP)





Please find information attached.


2020-564-FOI Request – Usage of antiretroviral therapies [321 KB PDF]